381 related articles for article (PubMed ID: 33171664)
1. Biotherapies in Uveitis.
Leclercq M; Desbois AC; Domont F; Maalouf G; Touhami S; Cacoub P; Bodaghi B; Saadoun D
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33171664
[TBL] [Abstract][Full Text] [Related]
2. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
[No Abstract] [Full Text] [Related]
3. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
4. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
Thomas AS
Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
[TBL] [Abstract][Full Text] [Related]
5. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
6. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
9. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
Rev Med Interne; 2018 Sep; 39(9):687-698. PubMed ID: 29610003
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion on the use of biological therapy in non-infectious uveitis.
Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
[TBL] [Abstract][Full Text] [Related]
12. [Ocular manifestations in Behçet's disease].
Desbois AC; Terrada C; Cacoub P; Bodaghi B; Saadoun D
Rev Med Interne; 2018 Sep; 39(9):738-745. PubMed ID: 29625716
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab in the treatment of non-infectious uveitis.
Burek-Michalska A; Turno-Kręcicka A
Adv Clin Exp Med; 2020 Oct; 29(10):1231-1236. PubMed ID: 33125196
[TBL] [Abstract][Full Text] [Related]
14. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis.
Thng ZX; Regenold J; Bromeo AJ; Akhavanrezayat A; Than NTT; Khatri A; Mohammadi SS; Tran ANT; Shin YU; Karaca I; Ghoraba HH; Or CCM; Nguyen QD
Expert Opin Investig Drugs; 2024 Feb; 33(2):95-104. PubMed ID: 38299551
[TBL] [Abstract][Full Text] [Related]
15. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
16. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review.
Busto-Iglesias M; Rodríguez-Martínez L; Rodríguez-Fernández CA; González-López J; González-Barcia M; de Domingo B; Rodríguez-Rodríguez L; Fernández-Ferreiro A; Mondelo-García C
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986627
[TBL] [Abstract][Full Text] [Related]
18. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview.
Valenzuela RA; Flores I; Urrutia B; Fuentes F; Sabat PE; Llanos C; Cuitino L; Urzua CA
Front Pharmacol; 2020; 11():655. PubMed ID: 32508634
[TBL] [Abstract][Full Text] [Related]
19. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
20. Miliary tuberculosis developing during adalimumab treatment for Behçet's disease with uveitis.
Kim MJ; Jones N; Steeples LR
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]